FDA Logo

FDA Issues ‘All-Hands’ Program to Battle Coronavirus, Boost Clinical Trial Efforts

The U.S. Food and Drug Administration (FDA) yesterday (March 31) unveiled the Coronavirus Treatment Acceleration Program (CTAP), which is designed to use “every tool at the agency’s disposal to bring new therapies to sick patients as quickly as possible, while at the same time supporting research to further evaluate whether these medical countermeasures are safe and effective for treating patients infected with this novel virus.”